Bioengineered liver system clears first human safety trial — and shows early promise

For patients with devastating liver failure who can't access a transplant in time, a new bioengineered liver system may offer a lifeline. The miroliverELAP — a single-use, extracorporeal device that mimics key liver functions — has cleared its first human safety test, with no serious or unexpected device-related adverse events reported in a small phase I trial presented at the AASLD annual meeting in Denver.

The system works by seeding a decellularized pig liver scaffold with human liver and endothelial cells sourced from donated livers deemed unsuitable for transplant. Seven critically ill patients received treatment, five of whom completed the full 48-hour therapy. Encouragingly, four of the five showed improvement in encephalopathy, and all five either came off vasopressors entirely or had their requirements cut by 75%.

By the Numbers:

• 7 critically ill patients enrolled; 5 completed therapy
• Mean MELD score: 36 (indicating severe liver disease)
• 3 of 5 patients who completed therapy were alive at 21 days post-treatment
• 4 of 5 patients showed improvement in encephalopathy
• All 5 patients saw vasopressor requirements eliminated or reduced by ≥75%

Why it matters: Acute liver failure is a race against the clock, and donor livers are scarce. A bioengineered bridge device could buy critical time — either for recovery or transplant — for patients who currently have no good options.